Clinical Trial Update: Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

View source ↗

Summary

A UK clinical trial evaluating brolucizumab for neovascular age-related macular degeneration has been terminated, according to the latest update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Status: TERMINATED